4.7 ms to 4.32 Ϯ 0.61 and 62.5 Ϯ 13.8 ms, respectively, but did not alter the open time constant ( o ). Mibefradil also failed to reduce the size of the unitary I AC current. A voltage-gated A-type K ϩ current was also inhibited by mibefradil at concentrations approximately 10-fold higher than those required to block I AC (IC 50 ϭ 4.65 M). These results identify mibefradil as a potent inhibitor of ATP-activated K ϩ channels in adrenal zona fasciculata cells. It appears to function by stabilizing closed states of these channels. In contrast to its selective block of T-type Ca 2ϩ channels, mibefradil may be a potent but less-selective K ϩ channel blocker. In this regard, the block of K ϩ channels may produce some of the toxicity associated with mibefradil in cardiovascular pharmacology.
Mibefradil is a new Ca
2ϩ antagonist that is effective as an antianginal and antihypertensive agent (Noll and Lusher, 1998) . Among Ca 2ϩ channel blockers, mibefradil is distinctive in its favorable hemodynamic actions and lack of side effects that are frequently observed with other Ca 2ϩ antagonists. At therapeutic concentrations, mibefradil reduces vascular resistance and heart rate without negative inotropy.
The favorable pharmacological profile of mibefradil and limited side effects appear to be related to selective block of T-type Ca 2ϩ channels. Unlike other Ca 2ϩ antagonists that are used clinically, mibefradil preferentially blocks T-type rather than L-type Ca 2ϩ channels with 10-to 20-fold selectivity (Mehrke et al., 1994; Mishra and Hermsmeyer, 1994a; Ertel, and Ertel, 1997) . Despite its desirable pharmacological and hemodynamic actions, mibefradil was removed from the market after it was shown to produce serious toxicity when taken in combination with a number of other drugs, including some H 1 antihistamine antagonists (Woosley, 1996) .
Although a number of studies have been performed that characterize the effects of mibefradil on various Ca 2ϩ channel subtypes and document its selective block of T-type channels, little is known about the effect of this drug on other types of ion-selective channels. In this regard, older Ca 2ϩ antagonists, such as the dihydropyridines, that preferentially block L-type Ca 2ϩ channels have also been shown to inhibit voltage-gated K ϩ channels, albeit at considerably higher concentrations (Hume, 1985; Nerbonne and Gurney, 1987; Mlinar and Enyeart, 1994) .
We studied the inhibition of K ϩ channels by mibefradil in whole-cell and single-channel patch-clamp recordings from bovine adrenal zona fasciculata (AZF) cells. These cells express a novel ATP-activated K ϩ channel (I AC ) that sets the membrane potential and couples adrenocorticotrophic hormone (ACTH) receptor activation to depolarization-dependent Ca 2ϩ entry and cortisol secretion (Mlinar et al., 1993; Enyeart et al., 1997) . Mibefradil potently blocks I AC K ϩ channels at concentrations below those required to inhibit T-type Ca 2ϩ channels in the same cells (Gomora et al., 1999) .
Materials and Methods
Tissue culture media, antibiotics, fibronectin, and FBS were obtained from Life Technologies (Grand Island, NY). Coverslips were from Bellco Glass (Vineland, NJ). Enzymes, MgATP, ACTH(1-24), and 1,2-bis(2-aminophenoxy)ethane-N,N,NЈ,NЈ-tetraacetic acid were obtained from Sigma Chemical Co. (St. Louis, MO). Mibefradil was a gift from Hoffman La Roche (Basel, Switzerland).
Isolation and Culture of AZF Cells. Bovine adrenal glands were obtained from steers (age range, 1-3 years) within 30 min of slaughter at a local slaughterhouse. Fatty tissue was removed immediately, and the glands were transported to the laboratory in ice-cold PBS containing 0.2% dextrose. Isolated AZF cells were prepared as previously described (Enyeart et al., 1997) . Cells were plated in Dulbecco's modified Eagle's medium/F-12ϩ in 35-mm dishes containing 9-mm 2 glass coverslips that had been treated with fibronectin (10 g/ml) at 37°C for 30 min and then rinsed with warm, sterile PBS immediately before adding cells. Dishes were maintained at 37°C in a humidified atmosphere of 95% air and 5% CO 2 . ] was 22 nM as determined using the Bound and Determined program (Brooks. and Storey, 1992) . The external solution consisted of 140 mM NaCl, 5 mM KCl, 2 mM CaCl, 2 mM MgCl 2 , 10 mM HEPES, and 5 mM glucose, pH 7.4 using NaOH. All solutions were filtered through 0.22-m cellulose acetate filters.
AZF cells were used for patch-clamp experiments 2 to 12 h after plating. Typically, cells with diameters of Ͻ15 m and capacitances of 8 to 12 pF were selected. Coverslips were transferred from 35-mm culture dishes to the recording chamber (volume, 1.5 ml), which was continuously perfused by gravity at a rate of 3 to 5 ml/min. For whole-cell recordings, patch electrodes with resistances of 1.0 to 2.0 M⍀ were fabricated from Corning 0010 glass (World Precision Instruments, Sarasota, FL). These routinely yielded access resistances of 1.5 to 4 M⍀ and voltage clamp-time constants of Ͻ100 s. For single-channel recordings, patch electrodes with higher resistances of 3 to 5 M⍀ were used. K ϩ currents were recorded at room temperature (22-25°C) according to the procedure of Hamill et al. (1981) with an Axopatch 1-D patch-clamp amplifier.
Pulse generation and data acquisition were done using a personal computer and pCLAMP software with a TL-1 interface (Axon Instruments, Inc., Burlingame, CA). Currents were digitized at 5 to 20 kHz after filtering with an 8-pole Bessel filter (Frequency Devices, Haverhill, MA). Linear leak and capacity currents were subtracted from current records using scaled hyperpolarizing steps of one-third to one-fourth amplitude. Data were analyzed and plotted using pCLAMP 5.5 and 6.02 (CLAMPAN, CLAMPFIT, FETCHAN, and PSTAT) and SigmaPlot 4.0. Drugs were applied by bath perfusion, which was controlled manually with a six-way rotary valve.
Results
Bovine AZF cells express two types of K ϩ currents: a voltage-gated, rapidly inactivating A-type current (I A ) and the noninactivating, ATP-activated current I AC (Mlinar et al., 1993; Mlinar and Enyeart, 1993; Enyeart et al., 1997) . I AC consists of two components: an apparent instantaneous component and a time-dependent component (Enyeart et al., 1996) . I AC is only weakly voltage dependent with open probability (P o ) increasing by ϳ30% between voltages of Ϫ40 and ϩ40 mV (Enyeart et al., 1997) .
In whole-cell recordings, I AC is present initially at low density but grows dramatically over a period of minutes, provided that ATP or other nucleotides are present at millimolar concentrations in the recording pipette (Enyeart et al., 1997) . The absence of time and voltage-dependent inactivation allow I AC to be easily isolated for measurement in wholecell recordings using either of two voltage-clamp protocols. When voltage steps of 300-ms duration were applied from a holding potential of Ϫ80 mV to a test potential of ϩ20 mV, I AC was measured selectively near the end of a voltage step where the rapidly inactivating A-type current had completely inactivated (Fig. 1A, left traces) . Alternatively, I AC was selectively activated with an identical voltage step, after a 10-s prepulse to Ϫ20 mV had fully inactivated the A-type current (Fig. 1A, right traces) .
Mibefradil applied to AZF cells externally through bath perfusion inhibited both noninactivating I AC and rapidly inactivating I A currents in AZF cells. Of these two currents, I AC was more potently inhibited. The rapidly inactivating I A current was also inhibited by mibefradil at ϳ10-fold higher concentrations.
In the experiment illustrated in Fig. 1 , I AC K ϩ current grew to a stable amplitude over a 15-min period before the cell was superfused with mibefradil at concentrations between 0.1 and 5 M. Over this range of concentrations, I AC was preferentially inhibited in a concentration-dependent manner (Fig. 1, A and B) . Inhibition was partially reversible with washing (Fig. 1B) . Overall, mibefradil inhibited I AC current with an IC 50 value of 0.50 M (Fig. 1C) . The inhibition of I AC by mibefradil was insensitive to changes in holding potential. Mibefradil (0.5 M) was equally effective at inhibiting I AC , activated from holding potential of Ϫ80 or Ϫ40 mV (data not shown).
ACTH (100 pM) selectively and completely suppresses the expression of I AC in whole-cell recordings, allowing the rapidly inactivating A-type current to be studied in isolation (Mlinar et al., 1993; Enyeart et al., 1996; Fig. 2A) . Under these conditions, mibefradil inhibits I A with an IC 50 value of 4.65 M (Fig. 2, A and B) . Inhibition of I A by mibefradil was slowly reversible. Washing with control saline reduced I A inhibition by 65.5 Ϯ 9.3% (n ϭ 6) after 15 to 20 min.
Block of Unitary I AC Currents by Mibefradil. Mibefradil inhibited unitary I AC K ϩ currents recorded from excised outside-out patches without reducing the amplitude of the single-channel current. Figure 3 shows unitary currents recorded from an outside-out patch in response to depolarizing steps to ϩ30 mV from a holding potential of Ϫ40 mV where I A channels are inactivated (Mlinar and Enyeart, 1993) . Under these conditions, a single type of K ϩ channel was typically present in the membrane patch. After recording currents in control saline, unitary currents were recorded at several different mibefradil concentrations.
Amplitude histograms constructed from unitary currents recorded in response to 80 to 96 separate voltage steps of 400-ms duration in control saline included three peaks indi- cating the presence of at least three active channels in the membrane patch (Fig. 3, right) . Gaussian fits to the data showed that each of these peaks was spaced at approximately multiples of the unitary current amplitude (3.50 Ϯ 0.08 pA). Mibefradil inhibited unitary I AC currents with the same potency observed in whole-cell recordings. Perfusion of mibefradil at concentrations of 1, 5, and 10 M reduced channel activity in a concentration-dependent manner (Fig. 3) . In the experiment illustrated, 10 M mibefradil reduced channel P o to nearly zero. Inhibition of I AC channel activity was rapidly reversed on washing with control saline and showed the tendency of I AC channel activity to increase spontaneously with time in outside-out patches (Fig. 3, bottom) . In this experiment, analysis of amplitude histograms showed that four functional I AC channels were present in the patch after reversal of the block by 10 M mibefradil. Figure 4A shows results from a similar experiment in which P o is plotted against time. The calculated P o was reduced from its control value of 0.21 to 0.07 and 0.02 by 1 and 5 M mibefradil, respectively. At a concentration of 10 M, channel openings were virtually eliminated. At each mibefradil concentration, inhibition was rapidly reversed on switching to control saline and revealed the underlying timedependent increase in P o . Results similar to these were obtained in each of eight cells. (Fig. 4B) . Overall, mibefradil (1 M) increased c1 and c2 from control values of 2.30 Ϯ 0.18 and 27.9 Ϯ 4.7 ms (n ϭ 9) to 4.32 Ϯ 0.61 and 62.50 Ϯ 13.80 ms (n ϭ 5), respectively. In contrast, in the presence of 1 M mibefradil, o was 1.25 Ϯ 0.07 ms (n ϭ 9 compared with a control value of 1.47 Ϯ 0.07 ms (n ϭ 9). 
Discussion
In this study, it was discovered that the T-type Ca 2ϩ channel antagonist mibefradil potently blocks ATP-activated I AC K ϩ channels in AZF cells. The inhibition of I AC K ϩ channels by mibefradil was voltage independent and, at the singlechannel level, appeared to reduce channel P o through stabilization of closed states. At 10-fold higher concentrations, mibefradil also inhibited voltage-gated, rapidly inactivating A-type K ϩ channels. Block of Ca 2؉ and K ؉ Channels by Mibefradil. Mibefradil inhibits I AC currents recorded in response to voltage steps from Ϫ80 with an IC 50 value of 0.50 M, a concentration 2-fold lower than that required to inhibit T-type Ca 2ϩ channels in the same cells under similar conditions (IC 50 ϭ 1.0 M; Gomora et al., 1999) . Mibefradil inhibits T currents in other cells, including cerebellar neurons and vascular smooth muscle cells, with potency similar to that observed in AZF cells (Mishra and Hermsmeyer, 1994b; McDonough and Bean, 1998) . In cells, including mouse spermatozoa, thyroid C cells, and rat sensory neurons, slightly higher IC 50 values have been reported for T channel inhibition (Mehrke et al., 1994; Arnoult et al., 1998; Todorovic and Lingle, 1998) . The relative potency of mibefradil as a T channel blocker is complicated because the drug displays prominent voltage and use dependence (see later). Regardless, in well-polarized cells, mibefradil blocks I AC -type K ϩ channels at concentrations lower than those required to block T-type Ca 2ϩ channels in a variety of cells.
Mibefradil exhibits 10-to 25-fold selectivity for T-type over L-type Ca 2ϩ channels (Mehrke et al., 1994; Bezprozvanny and Tsien, 1995; Ertel and Ertel, 1997) and as much as 200-fold selectivity for other Ca 2ϩ channel subtypes (Bezprozvanny and Tsien, 1995; McDonough and Bean, 1998) . By comparison, mibefradil blocks voltage-gated A-type K ϩ channels with an IC 50 value of 4.65 M, a concentration only 10-fold greater than that which blocks I AC channels. Overall, mibefradil may inhibit a variety of K ϩ channels at concentrations similar to those that block T-type Ca 2ϩ channels. In this regard, the ATP-activated I AC channel represents an interesting new type of K ϩ channel whose relationship to other K ϩ channels has not been determined. In developing a pharmacological profile of I AC channels, we previously found that established organic K ϩ channel blockers, including tetraethylammonium, 4-amino-pyridine, and quinidine, all inhibited I AC channels with a potency similar to that observed in many other voltage-gated K ϩ channels (Gomora and Enyeart, 1999). However, mibefradil was 50 to 10,000 times more potent than any of these agents as an inhibitor of I AC . The sensitivity of other major K ϩ channel subtypes, including inward rectifiers and dual-pore channels, to mibefradil has yet to be determined.
At the present, diphenylbutylpiperidine (DPBP) antipsychotic agents are the only other agents that block I AC channels with a potency similar to that of mibefradil. DPBPs, including penfluridol, pimozide, and fluspirilene, inhibit I AC with IC 50 values between 0. 19 and 0.35 M (Gomora and Enyeart, 1999) . Interestingly, DPBPs potently and preferentially block T-type Ca 2ϩ channels in many cells, including those of the AZF (Enyeart et al., 1992 (Enyeart et al., , 1993 . The molecular basis for this pharmacological similarity between T-type Ca 2ϩ channels and I AC K ϩ channels is currently unknown.
Mechanism of Mibefradil Inhibition of I AC K
؉ Channels. Mibefradil-mediated inhibition of T-type Ca 2ϩ channels shows prominent voltage and use dependence (McDonough and Bean, 1998; Gomora et al., 1999) . As a result, its potency increases markedly in response to sustained or repeated depolarizations. According to the "modulated receptor hypothesis," voltage-and use-dependent block occurs when drugs preferentially bind to channels that have been opened or inactivated by depolarization (Hille, 1977; Hondeghem and Katzung, 1977) .
In contrast to T-type Ca 2ϩ channels, I AC K ϩ channel gating is primarily regulated by ATP and metabolic factors. These channels exhibit very little voltage-dependent activation, and they do not inactivate (Mlinar et al., 1993; Enyeart et al., 1996 Enyeart et al., , 1997 . Consequently, block of I AC K ϩ channels by mibefradil likely occurs through an entirely different mechanism.
Accordingly, at the whole-cell level, the potency of mibefradil as an inhibitor of I AC K ϩ channels did not vary when Mechanism of Toxicity. Despite its beneficial hemodynamic effects, mibefradil has been withdrawn from the market due to toxicity associated with its use. The inhibition of cytochrome P-450 3A4 enzyme by mibefradil may result in numerous toxic drug interactions. Notably, when mibefradil is used in combination with certain antihistamines, such as astemizole, the Q-T interval is prolonged and ventricular arrhythmias may occur. The cellular mechanism probably involves inhibition of K ϩ channels in the myocardium by elevated concentrations of the antihistamine (Woosley, 1996) . The ability of mibefradil to potently block some types of K ϩ channels suggests that in addition to altering the pharmacodynamics of antihistamines, the cardiovascular toxicity produced by the combination of these drugs could be due to their combined direct inhibition of K ϩ channels in the heart.
In summary, mibefradil is a potent antagonist of ATPactivated K ϩ channels in bovine AZF cells. This agent will be useful in determining the function of this novel K ϩ channel in AZF cell physiology. Regardless of the ability of mibefradil to preferentially block T-type Ca 2ϩ channels, the parallel inhibition of K ϩ channels by this drug with equal or greater potency defines a limitation to its specificity as an ion channel blocker and suggests that interaction with K ϩ channels may be involved in its therapeutic or toxic effects. 
